Last reviewed · How we verify

NCT07514949: SOLUTION-ICD

The Feasibility and Safety of RK-4 Injection Bypassing Blood-brain Barrier in the Treatment of Acute Large Hemispheric Infarction Using Intracalvariosseous Injection Device

Not yet recruiting NA Last updated 7 April 2026
What this trial tests

NA trial testing RK-4 ICO injection in Stroke in 6 participants. Not yet recruiting.

Timeline
15 April 2026
Primary endpoint
15 November 2026
15 November 2026

Quick facts

Lead sponsoryilong Wang
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment6
Start date15 April 2026
Primary completion15 November 2026
Estimated completion15 November 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

yilong Wang — full company profile →

Who can join

Adults 18 to 80, any sex, with Stroke or Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A pilot study confirmed the feasibility and safety of neuroprotectant RK-4 intracalvariosseous(ICO) injection in patients with malignant middle cerebral artery infarction (mMCAI), showing a trend in improving 90-day functional scores compared to conventional treatment. The aim of this trial is to investigate the feasibility and safety of neuroprotective agent RK-4 injection using intracalvariosseous injection device in patients with acute large hemispheric infarction (LHI) who has contraindications of reperfusion therapy or have got poor reperfusion therapy outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other yilong Wang trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07514949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing